Acromegaly - The Annual Endocrine Society of Australia Seminar ...

More documents

Recommendations

Info

Medical <strong>The</strong>rapy Side effects include gallstones, GI upset, hyperglycemia, hair loss Subcutaneous octreotide tid or qid particularly useful if cost or headache control are issues
Growth Hormone Receptor Antagonist (Pegvisomant) Serum IGF-I (ng/mL) 2500 2000 1500 1000 500 van der Lely et al Lancet 2001:358;1754 • up to 40 mg/day • 97% normalized IGF-I 16-24 25-39 40-54 Age (years) 90 patients, 12 mo 55+
Page 1 and 2: Acromegaly Endocrine Society of Aus
Page 3 and 4: Case 1 45 yo male sent to PCP beca
Page 5 and 6: MRI scan: microadenoma
Page 7 and 8: Biochemical Diagnostic Testing Ran
Page 9 and 10: Therapy Surgery is primary therape
Page 11 and 12: Post-Surgical Assessment (A) Immed
Page 13 and 14: Case 1, contd. 12 week serum IGF-1
Page 15 and 16: Case 2 48 yo female with joint pai
Page 17 and 18: Pre-operative Medical Therapy? Imp
Page 19 and 20: Peri-operative risk with acromegaly
Page 21 and 22: Therapy of Residual Disease after S
Page 23 and 24: Biochemical Monitoring on Medical T
Page 25: Medical Therapy Somatostatin Analo
Page 29 and 30: Case 2, contd Because of residual
Page 31 and 32: SSA resistant acromegaly: Increase
Page 33 and 34: van der Lely, Eur J Endo 2011;164:3
Page 35 and 36: Radiation Therapy: Types Conventio
Page 37 and 38: Back to case… Macroadenoma CS inv
Page 39 and 40: Case 3 Macroadenoma CS involvement
Page 41 and 42: Additional Monitoring: Comorbiditie
Page 43 and 44: Additional Monitoring: Comorbiditie
Page 45 and 46: Pregnancy and Acromegaly Limited d
Page 47: Pregnancy and Acromegaly Once pati

Acromegaly - The Annual Endocrine Society of Australia Seminar ...

Create successful ePaper yourself

Delete template?

Save as template?